Repro-Med Systems, Inc. ( (KRMD) ) has released its Q1 earnings. Here is a breakdown of the information Repro-Med Systems, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
KORU Medical Systems, Inc. is a leading medical technology company specializing in the development, manufacturing, and commercialization of innovative large volume subcutaneous infusion solutions, primarily serving the healthcare sector with a focus on patient-centric care.
In its latest earnings report, KORU Medical Systems announced record financial results for the first quarter of 2025, with significant growth in net revenues and gross profit, alongside an optimistic revision of its revenue guidance for the full year.
The company reported a notable 18% increase in net revenues, reaching $9.6 million, driven by a 21% growth in its core business both domestically and internationally. Gross profit also saw a 19% rise, amounting to $6.0 million, with a slight improvement in gross margin. KORU Medical’s strategic plans include submitting two commercialized drugs for FDA 510(k) clearance by the end of the year, further solidifying its market position.
Despite a challenging economic environment, KORU Medical’s strong start to the year and strategic advancements in its product pipeline have led to an upward revision of its full-year revenue guidance to $38.5 – $39.5 million. The company remains confident in maintaining positive cash flow from operations and achieving its gross margin targets.
Looking ahead, KORU Medical Systems is poised to continue its growth trajectory, supported by its innovative product offerings and strategic market expansions, as it navigates the evolving healthcare landscape.